Video

Nonsteroidal Mineralcorticoid Receptor Antagonists in Managing Hyperkalemia

Dr. Cary Boyd-Shiwarski explains how nonsteroidal mineralcorticoid receptor antagonists and novel potassium-binding agents alter the management of hyperkalemia and approaching potassium handling in chronic kidney disease.

Pharmacy Times spoke to Dr. Cary Boyd-Shiwarski about her session at the ASN 2021 conference titled "Mechanisms of Potassium Handling in CKD."

Boyd explained how nonsteroidal mineralcorticoid receptor antagonists and novel potassium-binding agents alter the management of hyperkalemia and approaching potassium handling in chronic kidney disease.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Monoclonal antibodies are used to treat lung cancer. They are created in a lab and designed to target specific proteins on cancer cells, stopping them from growing and dividing.
Gene therapy in lung cancer (LC) - isometric view 3d illustration
© 2025 MJH Life Sciences

All rights reserved.